Aduro BioTech, Inc. (NASDAQ: ADRO) was founded in 2000 and is headquartered in Berkeley, California, with 143 full-time employees. It is a company that develops immunotherapy for pancreatic cancer.
On October 5, 2020, Chinook Therapeutics, Inc. , a Canadian clinical-stage biotechnology company that develops and commercializes precision drugs for kidney diseases , completed the merger with Aduro Biotech, Inc., and the combined company is called Chinook Therapeutics. It will start trading on the Nasdaq Global Select Market on October 6, 2020, with the trading code ” KDNY “.
Aduro BioTech (ADRO):
Aduro BioTech has continued to receive funding from the day of its listing. It can be seen from the increase. In addition, in order to create momentum for Aduro’s listing, Novartis has expanded the IO space to make preclinical asset valuations continue to rise: On March 31, 2015, Novartis announced that it would cooperate with Aduro. Biotech collaborated to develop its cyclic dinucleoside interferon gene activation protein (STING) ligand. Novartis will make a down payment of 200 million U.S. dollars and the mileage may reach 500 million U.S. dollars. Novartis will also acquire a 2.7% stake in Aduro for US$25 million and will invest US$25 million to develop this product.
ADRO is a tumor immunotherapy biotechnology company focusing on the development of durable and strong immune response mechanisms. Aduro BioTech’s leading product candidate is targeted at metastatic pancreatic cancer and is currently in clinical phase II. Tumor immunotherapy uses the body’s immune system to slow down and eliminate tumor cells. The key point that distinguishes us from ordinary tumor immunotherapy is that we can not only initiate an innate immune response, but also provide a strong and durable specific immune response.
The frontier of research in the field of immunotherapy is combination therapy with a wide range of indications. In order to integrate the response mechanism, safety and multi-function advantages of other therapies, adro combines its own platform with them. At present, the core candidates in their R&D pipeline come from the live attenuated double removal (LADD) Listeria immune platform and circulating dinucleotide (CDS).
Aduro BioTech’s leading product CRS-207 is used for metastatic pancreatic cancer and unresectable malignant pleural mesothelial cancer. The results of the second phase of clinical trials show that CRS-207 and GVAX immune vaccines constitute a cocktail therapy to achieve better results. The second phase of the test was designed with the CRS-207+GVAX combination and the GVAX group alone. The start and stop time of the test meets the requirements of DMC. According to FDA regulations, the identification of breakthrough therapy drugs must meet serious or life-threatening conditions.
Aduro BioTech’s products CRS-207 and GVAX have obtained FDA orphan drug certification for the treatment of pancreatic cancer. Orphan drug certification has two benefits: one is to obtain certain financial support, and the other is to obtain the right to monopolize the market in a specific environment. The patented product candidates we are developing include prostate cancer and lung cancer drugs in collaboration with Johnson & Johnson. Our two major scientific research platforms and other drug candidates have patent rights and are expected to be operational and developed until 2030.
Cancer immunotherapy is an emerging field of cancer treatment. Generally speaking, it is to weaken or kill cancer cells by activating or enhancing the immune mechanism of the cancer cell microenvironment. One area of rapid development of cancer immunotherapy is checkpoint inhibitors. This therapy has shown great potential and can even treat some cases where traditional methods have failed.
Candidate products developed based on ADRO’s two major technology platforms can activate the human body’s innate and specific responses and are more effective than current therapies. Based on the mechanism of action and safety, QDRO decided to establish an in-depth R&D pipeline with LADD and CDN as the main body, and combine it with some traditional and new therapies at any time. For example, checkpoint inhibitors are also their key considerations.
ADRO’s corporate vision is to use its own science and technology and a deep understanding of the interaction mechanism between human innate immunity and specific immunity to develop safer and effective cancer treatments for the benefit of mankind.
Why is ADRO attracted so much attention? Look at a report:
Cancer is already intimidating, and pancreatic cancer, also known as the king of cancer, has a very high mortality rate. With the current world-leading medical level in the United States, the incidence of pancreatic cancer in the United States is about 46,000 each year, and the death toll is close to 40,000. Pancreatic cancer ranks as the 4th most common cause of cancer death in American men (after lung, prostate, and colorectal cancer) and women (after lung, breast, and colorectal cancer).
The level of medical care in the United States ranks among the best in the world. But for the treatment of pancreatic cancer, the United States currently has only surgery, radiotherapy, chemotherapy, targeted therapy, biological therapy and other methods. Pancreatic cancer is diagnosed with a mortality rate of nearly 99%, which is almost equal to the gallows, just waiting for death. The moment came.
Let us first review gene tumor immunotherapy. At the end of 2013, the American Society of Hematology (ASH) American Blood Conference, attended by more than 100 countries, companies such as BLCM and KITE successively released relevant data on CAR-T therapy. Making CAR-T cell therapy may become one of the most likely means to cure cancer.
It caused a sensation for a while. CAR-T therapy-chimeric antigen receptor T cell immunotherapy. This is a new type of cell therapy that has been around for many years, first started in the 1990s, but has only been improved and used in clinics in recent years. Similar to other immunotherapy, its basic principle is to use the patient’s own immune cells to eliminate cancer cells. It can be said that CAR-T therapy makes the dream of curing tumors come true, direct and effective. It is a disruptive breakthrough in anti-cancer research. The subsequent other medical conferences across the United States made the market and the Huajie Fund very optimistic. It can be said that a large amount of capital has poured into these companies, which strongly promotes these CAR-T therapy companies such as: Kite Pharma(NASDAQ:KITE) Juno Therapeutics (NASDAQ:JUNO) Bellicum Pharmaceuticals (NASDAQ:BLCM) and other stocks rose sharply.
Aduro Biotech’s main product of GVAX vaccine for pancreatic cancer and prostate cancer was actually first developed by BPAX, but because the company was subsequently acquired by ANI Pharmaceuticals and turned to Aduro Biotech. This core technology focusing on the discovery and development of next-generation tumor immunotherapy for the STING pathway is tumor immunotherapy based on interferon-stimulated genes. Aduro’s preclinical drug candidate is a cyclic dinucleotide, which is expressed by bacteria and immune cells, which stimulates the response of STING, which can help the human immune system to better recognize and attack tumor cells.
In the former United States, most pancreatic cancer treatments use Celgene’s abraxane, which can only allow patients to live a few more months. It is this kind of therapy with unsatisfactory results, and the annual market sales can reach about 1.6 billion US dollars.
Aduro Biotech has such a good drug that has long attracted the attention of major pharmaceutical companies. Johnson & Johnson (NYSE: JNJ) and Novartis (NYSE: NVS ) invested in shares last year and early this year. Aduro is responsible for business activities in the United States and formulating sales plans, while Novartis is responsible for business activities in other regions outside the United States. Novartis and Aduro will share profits in the United States, Japan and major European countries, and Aduro will also enjoy Novartis’ sales commissions in other regions.
At the same time, as early as the company’s B round of venture capital, Morningside Ventures entered the market and invested 20 million US dollars. Stephanie O’Brien, who represents the fund, has also joined the Aduro board of directors to guide subsequent venture capital funds and commit to the company. IPO. Stephanie O’Brien is a professional investment in biomedicine. In this year’s D round, OrbiMed, Janus Capital Management LLC, etc. enter the market.
Aduro BioTech investment:
ADRO was listed on NASDAQ on April 15, 2015, with an issue price of US$17. Once it was issued, it was looted everywhere. The stock price reached 49.25 US dollars the next day, an increase of 189.7%.
Due to merge code changes!